"Well, I am very delighted to announce that we have sealed the deal on a new five-year strategic agreement with the federal government, which will commence at the conclusion of the current agreement on 1 July 2022," Medicines Australia CEO Liz de Somer told BioPharmaDispatch. …
MA delighted at the agreement's 'really ambitious reform agenda'
September 7, 2021 Latest NewsBioPharmaBioPharmaDispatch Executive
Latest Video
New Stories
-
Nasal adrenaline to be added to the PBS for people at risk of anaphylaxis
June 30, 2026 - - Latest News -
When it comes to negotiating with government, trust actions and not words
June 30, 2026 - - Latest News -
Neuren partner secures critical European backing for Rett syndrome therapy
June 30, 2026 - - Australian Biotech -
Disappointment for CSL as Europe recommends reversing approval of therapy
June 30, 2026 - - BioPharma -
Ipsen therapy approved in Australia for rare genetic disorder
June 30, 2026 - - Latest News -
New MSD vaccine listed on national program with expanded eligibility
June 30, 2026 - - Latest News -
A comment that highlights how complexity is making the challenge more challenging
June 29, 2026 - - Latest News